Heterocyclic compounds and methods of use
    5.
    发明授权
    Heterocyclic compounds and methods of use 失效
    杂环化合物和使用方法

    公开(公告)号:US07183304B2

    公开(公告)日:2007-02-27

    申请号:US10495992

    申请日:2002-11-20

    摘要: Compounds of the formula provide pharmacological agents which are potent agonists of Peroxisome Proliferator-Activated Receptors (PPARs). Accordingly, the compounds of the instant invention are useful for the treatment of conditions mediated by the PPAR receptor activity in mammals. Such conditions include dyslipidemia, hyperlipidemia, hypercholesteremia, atherosclerosis, hypertriglyceridemia, heart failure, myocardial infarction, vascular diseases, cardiovascular diseases, hypertension, obesity, inflammation, arthritis, cancer, Alzheimer's disease, skin disorders, respiratory diseases, ophthalmic disorders, inflammatory bowel diseases, ulcerative colitis and Crohn's disease. The compounds of the present invention are particularly useful in mammals as hypoglycemic agents for the treatment and prevention of conditions in which impaired glucose tolerance, hyperglycemia and insulin resistance are implicated, such as type-1 and type-2 diabetes, and Syndrome X. Preferred are the compounds of the invention which are dual agonists of PPARα and PPARγ receptors.

    摘要翻译: 配方的化合物提供作为过氧化物酶体增殖物激活受体(PPARs)的有效激动剂的药理学试剂。 因此,本发明的化合物可用于治疗由哺乳动物中的PPAR受体活性介导的病症。 这些病症包括血脂异常,高脂血症,高胆固醇血症,动脉粥样硬化,高甘油三酯血症,心力衰竭,心肌梗塞,血管疾病,心血管疾病,高血压,肥胖症,炎症,关节炎,癌症,阿尔茨海默病,皮肤病,呼吸系统疾病,眼科疾病,炎症性肠病 ,溃疡性结肠炎和克罗恩病。 本发明的化合物在哺乳动物中特别可用作降血糖药,用于治疗和预防葡萄糖耐量降低,高血糖症和胰岛素抵抗等疾病,如1型和2型糖尿病,以及X综合征。 是本发明的化合物,它们是PPARα和PPARγ受体的双重激动剂。

    CALCIUM SALTS OF INDOLE DERIVED STATINS
    6.
    发明申请
    CALCIUM SALTS OF INDOLE DERIVED STATINS 审中-公开
    单位衍生统计的钙盐

    公开(公告)号:US20100249204A1

    公开(公告)日:2010-09-30

    申请号:US12768991

    申请日:2010-04-28

    CPC分类号: C07D209/24

    摘要: The present invention provides calcium salts of indole derived statins of the formula wherein R1 is alkyl, cycloalkyl or aralkyl; R2, R3 and R4 are independently hydrogen, halogen or alkyl; R5 and R6 are independently hydrogen, halogen, alkyl, cycloalkyl, aralkyl, alkoxy or aralkoxy; and the hydroxyl group at the 3-position is in the R-configuration and at the 5-position in the S-configuration; or an enantiomer thereof; or a hydrate thereof; as obtainable by the methods of the present invention. More specifically, the invention provides a calcium salt of formula IA wherein R1 is isopropyl, R2 is fluorine and R3, R4, R5 and R6 are hydrogen, designated herein as Fluvastatin calcium, in a highly crystalline form. Furthermore, the present invention is directed to methods for the preparation of the crystalline Fluvastatin calcium, and to pharmaceutical compositions comprising the crystalline form.

    摘要翻译: 本发明提供下式的吲哚衍生的他汀类钙盐:其中R1是烷基,环烷基或芳烷基; R2,R3和R4独立地是氢,卤素或烷基; R5和R6独立地是氢,卤素,烷基,环烷基,芳烷基,烷氧基或芳烷氧基; 3位的羟基为R构型,S构型为5位; 或其对映体; 或其水合物; 如通过本发明的方法可获得的。 更具体地,本发明提供式IA的钙盐,其中R 1是异丙基,R 2是氟,并且R 3,R 4,R 5和R 6是氢,在本文中称为氟伐他汀钙,为高度结晶形式。 此外,本发明涉及制备结晶氟伐他汀钙的方法以及包含结晶形式的药物组合物。